Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein

Akito Nozaki, Masanori Ikeda, Atsushi Naganuma, Takashi Nakamura, Michiharu Inudoh, Katsuaki Tanaka, Nobuyuki Kato

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

Bovine and human lactoferrins (LF) prevent hepatitis C virus (HCV) infection in cultured human hepatocytes; the preventive mechanism is thought to be the direct interaction between LF and HCV. To clarify this hypothesis, we have characterized the binding activity of LF to HCV E2 envelope protein and have endeavored to determine which region(s) of LF are important for this binding activity. Several regions of human LF have been expressed and purified as thioredoxin-fused proteins in Escherichia coli. Far-Western blot analysis using these LF fragments and the E2 protein, expressed in Chinese hamster ovary cells, revealed that the 93 carboxyl amino acids of LF specifically bound to the E2 protein. The 93 carboxyl amino acids of LFs derived from bovine and horse cells also possessed similar binding activity to the E2 protein. In addition, the amino acid sequences of these carboxyl regions appeared to show partial homology to CD81, a candidate receptor for HCV, and the binding activity of these carboxyl regions was also comparable with that of CD81. Further deletion analysis identified 33 amino acid residues as the minimum binding site in the carboxyl region of LF, and the binding specificity of these 33 amino acids was also confirmed by using 33 maltose-binding protein-fused amino acids. Furthermore, we demonstrated that the 33 maltose-binding protein-fused amino acids prevented HCV infection in cultured human hepatocytes. In addition, the site-directed mutagenesis to an Ala residue in both terminal residues of the 33 amino acids revealed that Cys at amino acid 628 was determined to be critical for binding to the E2 protein. These results led us to consider the development of an effective anti-HCV peptide. This is the first identification of a natural protein-derived peptide that specifically binds to HCV E2 protein and prevents HCV infection.

Original languageEnglish
Pages (from-to)10162-10173
Number of pages12
JournalJournal of Biological Chemistry
Volume278
Issue number12
DOIs
Publication statusPublished - Mar 21 2003

Fingerprint

Viral Envelope Proteins
Lactoferrin
Viruses
Hepacivirus
Amino Acids
Peptides
Proteins
Virus Diseases
Maltose-Binding Proteins
Hepatocytes
Far-Western Blotting
Virus Attachment
Thioredoxins
Escherichia coli Proteins
Mutagenesis
Site-Directed Mutagenesis
Cricetulus
Horses
Amino Acid Sequence
Ovary

ASJC Scopus subject areas

  • Biochemistry

Cite this

Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. / Nozaki, Akito; Ikeda, Masanori; Naganuma, Atsushi; Nakamura, Takashi; Inudoh, Michiharu; Tanaka, Katsuaki; Kato, Nobuyuki.

In: Journal of Biological Chemistry, Vol. 278, No. 12, 21.03.2003, p. 10162-10173.

Research output: Contribution to journalArticle

Nozaki, Akito ; Ikeda, Masanori ; Naganuma, Atsushi ; Nakamura, Takashi ; Inudoh, Michiharu ; Tanaka, Katsuaki ; Kato, Nobuyuki. / Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein. In: Journal of Biological Chemistry. 2003 ; Vol. 278, No. 12. pp. 10162-10173.
@article{e5aff27c5c35463a8bd9c394f544689b,
title = "Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein",
abstract = "Bovine and human lactoferrins (LF) prevent hepatitis C virus (HCV) infection in cultured human hepatocytes; the preventive mechanism is thought to be the direct interaction between LF and HCV. To clarify this hypothesis, we have characterized the binding activity of LF to HCV E2 envelope protein and have endeavored to determine which region(s) of LF are important for this binding activity. Several regions of human LF have been expressed and purified as thioredoxin-fused proteins in Escherichia coli. Far-Western blot analysis using these LF fragments and the E2 protein, expressed in Chinese hamster ovary cells, revealed that the 93 carboxyl amino acids of LF specifically bound to the E2 protein. The 93 carboxyl amino acids of LFs derived from bovine and horse cells also possessed similar binding activity to the E2 protein. In addition, the amino acid sequences of these carboxyl regions appeared to show partial homology to CD81, a candidate receptor for HCV, and the binding activity of these carboxyl regions was also comparable with that of CD81. Further deletion analysis identified 33 amino acid residues as the minimum binding site in the carboxyl region of LF, and the binding specificity of these 33 amino acids was also confirmed by using 33 maltose-binding protein-fused amino acids. Furthermore, we demonstrated that the 33 maltose-binding protein-fused amino acids prevented HCV infection in cultured human hepatocytes. In addition, the site-directed mutagenesis to an Ala residue in both terminal residues of the 33 amino acids revealed that Cys at amino acid 628 was determined to be critical for binding to the E2 protein. These results led us to consider the development of an effective anti-HCV peptide. This is the first identification of a natural protein-derived peptide that specifically binds to HCV E2 protein and prevents HCV infection.",
author = "Akito Nozaki and Masanori Ikeda and Atsushi Naganuma and Takashi Nakamura and Michiharu Inudoh and Katsuaki Tanaka and Nobuyuki Kato",
year = "2003",
month = "3",
day = "21",
doi = "10.1074/jbc.M207879200",
language = "English",
volume = "278",
pages = "10162--10173",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "12",

}

TY - JOUR

T1 - Identification of a lactoferrin-derived peptide possessing binding activity to hepatitis C virus E2 envelope protein

AU - Nozaki, Akito

AU - Ikeda, Masanori

AU - Naganuma, Atsushi

AU - Nakamura, Takashi

AU - Inudoh, Michiharu

AU - Tanaka, Katsuaki

AU - Kato, Nobuyuki

PY - 2003/3/21

Y1 - 2003/3/21

N2 - Bovine and human lactoferrins (LF) prevent hepatitis C virus (HCV) infection in cultured human hepatocytes; the preventive mechanism is thought to be the direct interaction between LF and HCV. To clarify this hypothesis, we have characterized the binding activity of LF to HCV E2 envelope protein and have endeavored to determine which region(s) of LF are important for this binding activity. Several regions of human LF have been expressed and purified as thioredoxin-fused proteins in Escherichia coli. Far-Western blot analysis using these LF fragments and the E2 protein, expressed in Chinese hamster ovary cells, revealed that the 93 carboxyl amino acids of LF specifically bound to the E2 protein. The 93 carboxyl amino acids of LFs derived from bovine and horse cells also possessed similar binding activity to the E2 protein. In addition, the amino acid sequences of these carboxyl regions appeared to show partial homology to CD81, a candidate receptor for HCV, and the binding activity of these carboxyl regions was also comparable with that of CD81. Further deletion analysis identified 33 amino acid residues as the minimum binding site in the carboxyl region of LF, and the binding specificity of these 33 amino acids was also confirmed by using 33 maltose-binding protein-fused amino acids. Furthermore, we demonstrated that the 33 maltose-binding protein-fused amino acids prevented HCV infection in cultured human hepatocytes. In addition, the site-directed mutagenesis to an Ala residue in both terminal residues of the 33 amino acids revealed that Cys at amino acid 628 was determined to be critical for binding to the E2 protein. These results led us to consider the development of an effective anti-HCV peptide. This is the first identification of a natural protein-derived peptide that specifically binds to HCV E2 protein and prevents HCV infection.

AB - Bovine and human lactoferrins (LF) prevent hepatitis C virus (HCV) infection in cultured human hepatocytes; the preventive mechanism is thought to be the direct interaction between LF and HCV. To clarify this hypothesis, we have characterized the binding activity of LF to HCV E2 envelope protein and have endeavored to determine which region(s) of LF are important for this binding activity. Several regions of human LF have been expressed and purified as thioredoxin-fused proteins in Escherichia coli. Far-Western blot analysis using these LF fragments and the E2 protein, expressed in Chinese hamster ovary cells, revealed that the 93 carboxyl amino acids of LF specifically bound to the E2 protein. The 93 carboxyl amino acids of LFs derived from bovine and horse cells also possessed similar binding activity to the E2 protein. In addition, the amino acid sequences of these carboxyl regions appeared to show partial homology to CD81, a candidate receptor for HCV, and the binding activity of these carboxyl regions was also comparable with that of CD81. Further deletion analysis identified 33 amino acid residues as the minimum binding site in the carboxyl region of LF, and the binding specificity of these 33 amino acids was also confirmed by using 33 maltose-binding protein-fused amino acids. Furthermore, we demonstrated that the 33 maltose-binding protein-fused amino acids prevented HCV infection in cultured human hepatocytes. In addition, the site-directed mutagenesis to an Ala residue in both terminal residues of the 33 amino acids revealed that Cys at amino acid 628 was determined to be critical for binding to the E2 protein. These results led us to consider the development of an effective anti-HCV peptide. This is the first identification of a natural protein-derived peptide that specifically binds to HCV E2 protein and prevents HCV infection.

UR - http://www.scopus.com/inward/record.url?scp=0037855837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037855837&partnerID=8YFLogxK

U2 - 10.1074/jbc.M207879200

DO - 10.1074/jbc.M207879200

M3 - Article

VL - 278

SP - 10162

EP - 10173

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 12

ER -